Annovis Bio Files 8-K
Ticker: ANVS · Form: 8-K · Filed: May 6, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financial-statements
TL;DR
Annovis Bio filed a routine 8-K on May 6th, no major news.
AI Summary
Annovis Bio, Inc. filed an 8-K on May 6, 2024, reporting on its financial statements and exhibits. The company, previously known as QR Pharma, Inc., is incorporated in Delaware and headquartered in Malvern, PA. This filing does not appear to contain specific financial figures or material events beyond the standard reporting of exhibits.
Why It Matters
This 8-K filing serves as a standard disclosure for Annovis Bio, Inc., providing updates on its financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting financial statements and exhibits, with no new material information or significant events disclosed.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former company name
- May 6, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Annovis Bio, Inc.?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of May 6, 2024.
When was Annovis Bio, Inc. incorporated and where is its principal executive office located?
Annovis Bio, Inc. is incorporated in Delaware and its principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What was Annovis Bio, Inc.'s former company name?
Annovis Bio, Inc.'s former company name was QR Pharma, Inc.
What is the Commission File Number for Annovis Bio, Inc.?
The Commission File Number for Annovis Bio, Inc. is 001-39202.
Does this filing disclose any specific financial results or new material events?
Based on the provided text, this filing appears to be a standard report of financial statements and exhibits, and does not disclose specific financial results or new material events.
Filing Stats: 411 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-05-06 17:11:19
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2413238d2_8k.htm (8-K) — 24KB
- tm2413238d2_ex99-1.htm (EX-99.1) — 17KB
- 0001104659-24-057525.txt ( ) — 217KB
- anvs-20240506.xsd (EX-101.SCH) — 3KB
- anvs-20240506_lab.xml (EX-101.LAB) — 33KB
- anvs-20240506_pre.xml (EX-101.PRE) — 22KB
- tm2413238d2_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On May 6, 2024, Annovis Bio, Inc. (the "Company") issued a press release dated May 6, 2024 which is being furnished as Exhibit 99.1 hereto.
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated May 6, 2024 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: May 6, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer